New immunotherapy combo could ‘change the landscape’ of cancer treatment

A pair of new studies suggest that combining two different kinds of inhibitors could be a new effective approach to immunotherapy.

June 20, 2024 Check out STAT+

Sponsored By

Adobe STAT+ | New immunotherapy combination could 'change the landscape' of cancer treatment Two types of drugs, checkpoint inhibitors and JAK inhibitors, provide an unexpected synergy in treatment, according to new studies published in Science. By Angus Chen STAT+ | Doctors Without Borders is closing its widely regarded access-to-medicines campaign "It is a shocking blow, because the access campaign is a cornerstone of the wider access to medicines movement," said one expert. By Ed Silverman STAT+ | Zealand's amylin-targeting drug shows early potential in obesity Though these are early findings, they show that Zealand's injectable treatment has potential to deliver substantial weight loss. By Elaine Chen Arantza Pena for STAT Opinion: Journals that published Richard Lynn's racist 'research' articles should retract them Richard Lynn's work, especially his "national IQ" data, has been condemned as seriously flawed. It's time to retract these racist studies. By Dan Samorodnitsky, Kevin Bird, Jedidiah Carlson, James Lingford, Jon Phillips, Rebecca Sear, and Cathryn Townsend STAT+ | Gilead's twice-yearly antiviral protected women from HIV infection in large trial If confirmed in a second study, the data could set up lenacapavir to be approved as an option for pre-exposure prophylaxis, or PrEP, for HIV. By Jason Mast Listen: Fauci's memoir, Alnylam's tenuous trial, and a mid-year review This episode, we discuss: Can Alnylam find success with its latest cardiac treatment after tweaking the trial? By Allison DeAngelis and Adam Feuerstein STAT+ | A primer on HELIOS-B, an enormous stock-moving event for Alnylam Pharmaceuticals The results of HELIOS-B will also impact competitors, including BridgeBio Pharma and Ionis Pharmaceuticals. By Adam Feuerstein Coalition wages campaign for retractions of Richard Lynn's racist journal articles The group is urging Elsevier, Springer, and other publishers to retract the articles of Richard Lynn, who espoused ideas of racial superiority and eugenics. By Usha Lee McFarling

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser